ENvue Medical (FEED) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FEED SEC filings page.
ENvue Medical (FEED) reported $1.9M in revenue over the twelve months to Jun 30, 2026, down 17.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin collapse and goodwill expansion now dominate a business with essentially flat sales.
Revenue was essentially unchanged from FY2024 to FY2025, but gross margin fell from59.0% to6.0% . That combination points to a severe deterioration in unit economics or revenue mix, rather than a volume-driven earnings change.
The FY2025 net loss reached
Total assets rose from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ENvue Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ENvue Medical held $4.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and ENvue Medical scores 19/100 among other emerging companies.
ENvue Medical had 4M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and ENvue Medical scores 40/100 among other emerging companies.
ENvue Medical spent $1.8M on research and development in fiscal year 2025, which was 6.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and ENvue Medical scores 28/100 among other emerging companies.
ENvue Medical reported revenue of $2.6M in fiscal year 2025, against $2.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and ENvue Medical scores 50/100 among other emerging companies.
ENvue Medical's operations used $9.4M of cash in fiscal year 2025, against $2.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and ENvue Medical scores 12/100 among other emerging companies.
ENvue Medical's cash, cash equivalents and investments came to $4.2M at the end of fiscal year 2025, against $7.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and ENvue Medical scores 45/100 among other emerging companies.
ENvue Medical scores -4.58, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.3M) relative to total liabilities ($7.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ENvue Medical passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
ENvue Medical reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ENvue Medical generated $239K in revenue in Q2 2026. This represents a decrease of 51.6% from the same quarter a year earlier. Against the prior quarter it is down 63.4%.
ENvue Medical's EBITDA was -$5.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 45.5% from the same quarter a year earlier. Against the prior quarter it is down 50.4%.
ENvue Medical reported -$4.9M in net income in Q2 2026. This represents a decrease of 23.4% from the same quarter a year earlier. Against the prior quarter it is down 28.2%.
Cash & Balance Sheet
ENvue Medical recorded an outflow of $2.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 19.8% from the same quarter a year earlier. Against the prior quarter it is up 37.2%.
ENvue Medical held $1.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
ENvue Medical's ROE was -15.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 6.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.0 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ENvue Medical invested $510K in research and development in Q2 2026. This represents a decrease of 49.8% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
ENvue Medical invested $27K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 575.0% from the same quarter a year earlier. Against the prior quarter it is up 58.8%.
Not reported for Q2 2026.
FEED Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $239K-51.6% | $653K-36.3% | $312K-29.7% | $722K+92.0% | $494K-39.5% | $1.0M+11.3% | $444K-62.3% | $376K-17.9% |
| Cost of Revenue | $505K-4.5% | $708K+7.9% | $682K+323.6% | $533K+119.3% | $529K+36.0% | $656K+155.3% | $161K-63.4% | $243K+122.9% |
| Gross Profit | -$266K-660.0% | -$55K-114.9% | -$370K-230.7% | $189K+42.1% | -$35K-108.2% | $369K-44.4% | $283K-61.6% | $133K-61.9% |
| R&D Expenses | $510K-49.8% | $468K-11.7% | -$5K-98.6% | $221K-11.2% | $1.0M+443.3% | $530K+338.0% | $352K+467.7% | $249K+654.5% |
| SG&A Expenses | $3.5M+55.4% | $2.4M+80.0% | $2.6M+134.1% | $1.4M+108.5% | $2.3M+214.5% | $1.3M+41.9% | $1.1M-1.6% | $673K-15.5% |
| Operating Income | -$5.5M-37.7% | -$3.7M-100.4% | -$14.8M-981.3% | -$2.2M-131.6% | -$4.0M-489.9% | -$1.9M-226.1% | -$1.4M-95.2% | -$970K-44.8% |
| EBITDA | -$5.3M-45.5% | -$3.5M-90.5% | -$14.6M | -$2.0M-105.2% | -$3.6M | -$1.8M | N/A | -$970K-44.8% |
| Interest Expense | $30K-79.2% | $36K-32.1% | N/A | $53K+60.6% | $144K+323.5% | $53K+55.9% | $34K+3.0% | $33K-5.7% |
| Income Tax | -$2K-103.2% | $33K+120.0% | -$419K-8480.0% | $35K+1066.7% | $62K+1450.0% | $15K+114.3% | $5K-54.5% | $3K0.0% |
| Net Income | -$4.9M-23.4% | -$3.8M-104.2% | -$12.9M-798.1% | $510K+151.1% | -$4.0M-477.2% | -$1.9M-218.4% | -$1.4M-76.0% | -$998K-37.3% |
| EPS (Basic) | -$1.98-92.2% | -$6.88+77.0% | -$20.00-55.2% | -$0.91+74.4% | -$1.03+96.2% | -$29.90-1356.3% | -$12.89+40.3% | -$3.56-747.6% |
| EPS (Diluted) | -$1.98 | -$6.88 | -$20.00 | -$0.91 | -$1.03 | -$29.90 | -$12.89 | -$3.56 |
| Diluted Shares (Avg) | 6M | 3M | N/A | 858,434 | 484,566 | 62,615 | N/A | 280,318 |
FEED Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.4M-25.4% | $39.9M-9.6% | $41.1M+1033.2% | $54.4M+1061.5% | $51.5M+803.8% | $44.1M+607.4% | $3.6M-45.6% | $4.7M-36.4% |
| Current Assets | $4.8M-30.1% | $6.2M+60.6% | $7.3M+118.3% | $10.0M+128.8% | $6.9M+28.0% | $3.9M-35.1% | $3.3M-48.7% | $4.4M-38.9% |
| Cash & Equivalents | $1.1M-73.1% | $2.2M+291.4% | $4.2M+461.7% | $7.0M+432.6% | $4.0M+85.7% | $571K-78.9% | $752K-77.1% | $1.3M-65.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $2.6M+17.0% | $2.3M+12.2% | $2.3M+6.7% | $2.2M-0.3% | $2.2M-9.3% | $2.0M-22.0% | $2.2M-19.8% | $2.3M-29.2% |
| Accounts Receivable | $205K+78.3% | $332K-7.3% | $289K+194.9% | $252K-56.6% | $115K-76.5% | $358K-0.6% | $98K-69.2% | $580K+1712.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $29.1M-24.7% | $29.1M-14.2% | $29.1M | $38.6M | $38.6M | $33.9M | N/A | N/A |
| Total Liabilities | $7.6M-30.5% | $7.9M-6.8% | $7.6M+154.1% | $11.9M+324.2% | $11.0M+285.5% | $8.4M+208.7% | $3.0M+11.8% | $2.8M+5.2% |
| Current Liabilities | $7.3M+11.6% | $6.9M-16.3% | $6.7M+144.7% | $11.6M+361.9% | $6.5M+156.0% | $8.2M+237.9% | $2.7M+10.9% | $2.5M+5.4% |
| Non-Current Liabilities | $342K-92.3% | $991K+330.9% | $967K+245.4% | $275K-4.8% | $4.5M+1392.3% | $230K-24.3% | $280K+20.7% | $289K+3.6% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $1.3M | N/A | N/A |
| Total Equity | $30.8M-24.0% | $32.0M-10.3% | $33.5M+5242.4% | $42.5M+2168.4% | $40.5M+1324.7% | $35.7M+918.1% | $627K-84.3% | $1.9M-60.1% |
| Retained Earnings | -$124.4M-63.8% | -$112.1M-55.1% | -$90.5M-29.6% | -$76.9M-12.4% | -$76.0M-12.8% | -$72.3M-8.4% | -$69.8M-5.6% | -$68.4M-4.7% |
FEED Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M+20.5% | -$4.3M-221.1% | -$2.7M-388.3% | -$2.0M-135.6% | -$3.4M-511.8% | -$1.3M-132.0% | -$548K-11.6% | -$836K-22.6% |
| Depreciation & Amortization | $219K-39.8% | $217K+1105.6% | $258K | $257K | $364K | $18K | $0 | $0 |
| Capital Expenditures | $27K+575.0% | $17K+240.0% | $23K | $28K | $4K+100.0% | $5K+400.0% | $0 | $0 |
| Free Cash Flow | -$2.7M+19.8% | -$4.3M-221.1% | -$2.7M-392.5% | -$2.0M-139.0% | -$3.4M-510.3% | -$1.3M-132.4% | -$548K-11.6% | -$836K-22.6% |
| Investing Cash Flow | -$27K-575.0% | -$17K-111.9% | -$23K | -$28K | -$4K-100.0% | $143K+14400.0% | $0 | $0 |
| Financing Cash Flow | $1.6M-76.7% | $2.3M+122.9% | -$34K | $4.9M+18322.2% | $6.8M | $1.1M | $0 | -$27K-100.6% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
FEED Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -111.3% | -8.4%-44.4pp | -118.6% | 26.2%-9.2pp | -7.1%-59.5pp | 36.0%-36.1pp | 63.7%+1.1pp | 35.4%-40.8pp |
| Operating Margin | -2290.4% | -568.3% | -4748.1% | -311.2% | -804.9% | -180.7% | -308.6% | -258.0% |
| Net Margin | -2049.8% | -585.3% | -4119.2% | 70.6% | -803.9% | -182.6% | -322.3% | -265.4% |
| Return on Equity | -15.9%-6.1pp | -11.9%-6.7pp | -38.4%+189.9pp | 1.2%+54.5pp | -9.8%+14.4pp | -5.3%+11.5pp | -228.2%-207.8pp | -53.3%-37.8pp |
| Return on Assets | -12.8%-5.0pp | -9.6%-5.3pp | -31.3%+8.2pp | 0.9%+22.3pp | -7.7%+4.4pp | -4.2%+5.2pp | -39.4%-27.2pp | -21.3%-11.4pp |
| Current Ratio | 0.66-0.4x | 0.90+0.4x | 1.09-0.1x | 0.86-0.9x | 1.05-1.1x | 0.47-2.0x | 1.22-1.4x | 1.74-1.3x |
| Debt-to-Equity | 0.250.0x | 0.25+0.2x | 0.23-4.6x | 0.28-1.2x | 0.27-0.7x | 0.04-0.7x | 4.79+4.1x | 1.50+0.9x |
| Asset Turnover | 0.010.0x | 0.020.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.1x | 0.02-0.1x | 0.12-0.1x | 0.080.0x |
| FCF Margin | -1137.2% | -662.9% | -865.1% | -276.7% | -685.6% | -131.5% | -123.4% | -222.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Where ENvue Medical Ranks
Frequently Asked Questions
What is ENvue Medical's annual revenue?
ENvue Medical (FEED) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ENvue Medical's revenue growing?
ENvue Medical (FEED) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.
Is ENvue Medical profitable?
No, ENvue Medical (FEED) reported a net income of -$18.2M in fiscal year 2025.
What is ENvue Medical's EBITDA?
ENvue Medical (FEED) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ENvue Medical's gross margin?
ENvue Medical (FEED) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ENvue Medical's return on equity (ROE)?
ENvue Medical (FEED) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ENvue Medical's free cash flow?
ENvue Medical (FEED) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a -274.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ENvue Medical's operating cash flow?
ENvue Medical (FEED) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ENvue Medical's total assets?
ENvue Medical (FEED) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ENvue Medical's capital expenditures?
ENvue Medical (FEED) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ENvue Medical spend on research and development?
ENvue Medical (FEED) invested $1.8M in research and development during fiscal year 2025.
What is ENvue Medical's current ratio?
ENvue Medical (FEED) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is ENvue Medical's debt-to-equity ratio?
ENvue Medical (FEED) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ENvue Medical's return on assets (ROA)?
ENvue Medical (FEED) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ENvue Medical's P/E ratio?
ENvue Medical (FEED) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $3.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ENvue Medical's price-to-sales ratio?
ENvue Medical (FEED) trades at 1.7x sales, its market capitalization divided by revenue of $1.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ENvue Medical's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ENvue Medical (FEED) held $4.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ENvue Medical's Altman Z-Score?
ENvue Medical (FEED) has an Altman Z-Score of -4.58, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ENvue Medical's Piotroski F-Score?
ENvue Medical (FEED) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ENvue Medical's earnings high quality?
ENvue Medical (FEED) reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ENvue Medical?
ENvue Medical (FEED) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.